Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol
- 2 December 2022
- journal article
- letter
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (12) , 1473-1476
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocolHealth and Quality of Life Outcomes, 2019
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialThe Lancet Oncology, 2019
- Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2018
- Novel Agents and Drug Development Needs in Advanced Clear Cell Renal CancerJournal of Clinical Oncology, 2018
- Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback formHealth and Quality of Life Outcomes, 2018
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial ProtocolsJAMA, 2018
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Patient-Reported Physical Function Measures in Cancer Clinical TrialsEpidemiologic Reviews, 2017
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialJournal of Clinical Oncology, 2016